Dr. Abhinav Singh, S18157, Dr. Poninder Kumar Dogra, Dr. Brig (Mrs) Sagarika Patyal, Dr. (Col) Gaurav Kapoor
Objective: To evaluate the effect of intravitreal Anti VEGF (Ranibizumab 0.5mg) in CSCR with ink blot leakage and NSD> 3 months duration.
Study Design: Prospective Study.
Methodology: 20 eyes of 20 adult patients with CSCR were included in the study of duration 08 weeks. After informed consent, all patients were given intravitreal Ranibizumab 0.5mg. The outcome measures were BCVA status, CMT on OCT and changes in pattern of leaks on FFA, pre and post Anti VEGF at 02 and 08 weeks.
Results: At 08 weeks follow up, It was observed that the CSCR with ink blot pattern showed moderate visual gain, 66.6% decrease in leak intensity on FFA (p <0.001) & mean CMT on OCT showed 70% decrease (p <0.001) at 08 weeks follow up period.
Conclusion: Intravitreal Ranibizumab 0.5mg was associated with improvement in BCVA, mean CMT, decrease in intensity & delay in onset of ink blot pattern of leaks on FFA, NSD height on OCT.
Keywords: Central Serous Chorioretinopathy; Optical Coherence Tomography.